Hemophilia A and B - Epidemiology Forecast to 2030

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B (WFH, 2013). According to the WFH, only 4% of hemophilia A cases and 6% of hemophilia B cases are in women (WFH, 2020).

In the 8MM, the diagnosed prevalent cases of hemophilia A and hemophilia B are expected to increase from 73,437 cases in 2020 to 82,128 cases in 2030, at an Annual Growth Rate (AGR) of 1.18%. In 2030, China will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B in the 8MM, with 23,688 diagnosed prevalent cases, whereas Spain will have the fewest diagnosed prevalent cases with 2,975 cases. In the 8MM, the diagnosed prevalent cases of acquired hemophilia is expected to increase from 2,175 cases in 2020 to 2,210 cases in 2030, at an AGR of 0.16%. The analyst epidemiologists attribute the increase in the diagnosed prevalent cases of hemophilia A and hemophilia B to better diagnosis and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for hemophilia A and hemophilia B in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia A and hemophilia B. In this analysis, hemophilia is grouped into the groups: Hemophilia A (ICD-10 code = D66), hemophilia B (ICD-10 code = D67), hemophilia A and B, and acquired hemophilia (ICD-10 code = D68.311).
The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of each of the four groups. The diagnosed prevalent cases of hemophilia A and hemophilia B groups are further segmented by severity (mild, moderate, and severe) and inhibitor status. In addition, the diagnosed prevalent cases of hemophilia A and hemophilia B were further segmented by severity (mild, moderate, and severe), inhibitor status, severity among inhibitors, prophylaxis, and on-demand treatment.
The hemophilia A and B epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The hemophilia A and B epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
Quantify patient populations in the global hemophilia A and B market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for hemophilia A and B therapeutics in each of the markets covered.
Understand magnitude of hemophilia A and B by severity, inhibitors, severity among inhibitors, and type of treatment (prophylaxis and on-demand).

1 Hemophilia A and B: Executive Summary

1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 8MM Forecast Methodology
2.4.1 Sources
2.4.2 Sources Not Used
2.4.3 Forecast Assumptions and Methods
2.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
2.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia
2.5 Epidemiological Forecast for Hemophilia A (2020-2030)
2.5.1 Diagnosed Prevalent Cases of Hemophilia A
2.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
2.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
2.6 Epidemiological Forecast for Hemophilia B (2020-2030)
2.6.1 Diagnosed Prevalent Cases of Hemophilia B
2.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
2.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
2.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020-2030)
2.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
2.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
2.8 Discussion
2.8.1 Epidemiological Forecast Insight
2.8.2 COVID-19 Impact
2.8.3 Limitations of the Analysis
2.8.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Relationship of Bleeding Severity with Clotting Factor Level.
Table 4: Comorbidities for Hemophilia

List of Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, All Ages, 2020 and 2030
Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, N, All Ages, 2020 and 2030
Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), Both Sexes, All Ages
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), Both Sexes, All Ages
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Inhibitors
Figure 8: 8MM, Sources Used to Forecast the Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 9: 8MM, Sources Used to Forecast the Types of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, N, Both Sexes, All Ages, 2020
Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Age, N, Both Sexes
Figure 13: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Sex, N, All Ages, 2020
Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, N, Both Sexes, All Ages, 2020
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Age, N, Both Sexes
Figure 18: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Sex, N, All Ages, 2020
Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Age, N, Both Sexes, 2020
Figure 23: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex, N, All Ages, 2020
Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 27: 8MM, Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, N, Both Sexes, All Ages, 2020

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3894EUR$3,995USD£3,244GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7788EUR$7,990USD£6,488GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11682EUR$11,985USD£9,733GBP

Scope

Reasons to Buy

Table of Contents

Related Topics

Related Reports

Acquired Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Hemophilia B Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Hemophilia with Inhibitor - Market Insight, Epidemiology and Market Forecast - 2034

Acquired hemophilia A - Market Insight, Epidemiology and Market Forecast - 2034

Hemophilia Drugs - Global Strategic Business Report